Healthcare Artificial Intelligence (AI) Market Size to Reach Revenues of USD 44.5 Billion by 2026 - Arizton - Seite 2

Healthcare Artificial Intelligence (AI) Market – Segmentation

• The best use of AI hardware is by medical device companies and healthcare providers. Robotic surgery is one of the major segments with a wide adoption rate in healthcare. MedTech companies specialize in the invention, creation, and production of medical devices that can be used in different healthcare systems.
• Clinical work is needed to determine the underlying reason for symptoms, and diagnostic AI solutions may help by improving accuracy or saving time. Across the different diagnostic areas, we see a variety of applications for diagnostic tests, which start with simple to more sophisticated diagnostic applications such as OLO, an AI-enhanced blood testing device that counts blood cells at the point of care.
• Machine learning (ML) is a subset of AI that enables software applications to predict results more accurately. Machine learning algorithms use historical data as input to predict new outputs. It can give companies insight into trends in customer behavior and speed up business processes for new product development, being at the core of many leading companies today.

Healthcare Artificial Intelligence (AI) Market by Category

• Software & Services
• Hardware

Healthcare Artificial Intelligence (AI) Market by Application

• Hospital Workflow Management
• Medical Imaging and Diagnosis
• Drug Discovery and Precision Medicine
• Patient Management

Healthcare Artificial Intelligence (AI) Market by Technology

• Machine Learning
• Querying Method
• Natural Language Processing

Healthcare Artificial Intelligence (AI) Market by End-users

• Healthcare Providers
• Pharma-biotech and medical devices companies
• Payers
• Others

Healthcare Artificial Intelligence (AI) Market – Dynamics

Global key vendors from the pharmaceutical and biotech industry, such as Amgen, BASF, LEO, Eli Lilly, AstraZeneca, Bayer, Novartis, J&J, and Merck, are now a part of machine learning for pharmaceutical discovery. These vendors are making remarkable growth as AI-driven solutions are easy for the user interface and are creating analytical bookmarks on key drivers in sales to determine investments. For example, the collaboration of GSK with Exscientia identified a small compound for targeted therapeutics and its characteristics toward the specific target using AI platforms. Gilead Sciences and Insitro partnered to research on non-alcoholic steatohepatitis patients. Using machine learning and human genetics, Insitro identified discovery & development in therapeutics.